Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms (Q40874901)
scientific article
Language:
Current Data About Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms
(P31) (Q13442814)
(P248)
(P698) 10849376
(P813) Sunday, September 24, 2017

(P304) 634-641
(P248)
(P698) 10849376
(P813) Sunday, September 24, 2017

(P433) 6
(P248)
(P698) 10849376
(P813) Sunday, September 24, 2017

(P478) 51
(P248)
(P698) 10849376
(P813) Sunday, September 24, 2017

(P577) Thursday, June 1, 2000
(P248)
(P698) 10849376
(P813) Sunday, September 24, 2017

(P921) (Q412323)
(P887)

(P1433) (Q15762682)
(P248)
(P698) 10849376
(P813) Sunday, September 24, 2017

(P1476) "Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms" (language: en)
(P248)
(P698) 10849376
(P813) Sunday, September 24, 2017

(P2093) Harjunpää A
(P1545) 1
(P248)
(P698) 10849376
(P813) Sunday, September 24, 2017

Junnikkala S
(P1545) 2
(P248)
(P698) 10849376
(P813) Sunday, September 24, 2017

Meri S
(P1545) 3
(P248)
(P698) 10849376
(P813) Sunday, September 24, 2017

other details
description scientific article

External Links
(P356) 10.1046/J.1365-3083.2000.00745.X
(P698) 10849376
(P5875) 12469901